Document is current
Any future updates will be listed below
-
Authors
Morikawa, Kei
Takata, Saori
Tanaka, Hisashi
Itani, Hidetoshi
Ishihara, Masashi
Horiuchi, Kazuya
Kato, Yasuhiro
Ikemura, Shinnosuke
Nakagawa, Hideyuki
Nakahara, Yoshiro
Seki, Yoshitaka
Bessho, Akihiro
Takahashi, Nobumasa
Hayashi, Kentaro
Endoh, Takeo
Takeyama, Kiyoshi
Maekura, Toshiya
Takigawa, Nagio
Kawase, Akikazu
Endoh, Makoto
Nemoto, Kenji
Kishi, Kazuma
Soejima, Kenzo
Okuma, Yusuke
Yoshimura, Kenichi
Saigusa, Daisuke
Kanai, Yae
Ueda, Koji
Togashi, Akira
Matsutani, Noriyuki
Seki, Nobuhiko
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000024935 at UMIN JapanDocuments that mention this clinical trial
Efficacy and safety findings of the EXTRA study in older adult EGFR-mutant lung cancer patients receiving afatinib as first-line treatment
https://doi.org/10.1038/s41598-026-38944-3
-
Funding
Funding for this research was provided by:
Nippon Boehringer Ingelheim Co., Ltd.
- License Information
-
More Information
Article History
Received: 17 May 2024
Accepted: 2 February 2026
First Online: 11 February 2026
Competing Interests
: Kei Morikawa: personal fees as honoraria from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Eli Lilly, Takeda Pharmaceutical; Hisashi Tanaka: personal fees as honoraria from Ono Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Chugai Pharmaceutical, Boehringer Ingelheim, and Pfizer; Yoshitaka Seki: personal fees as honoraria from AstraZeneca, Eli Lilly, MSD, Ono Pharmaceutical, Novartis, Taiho Pharmaceutical, Chugai Pharmaceutical, Boehringer Ingelheim, Shionogi, Sanofi, Kyowa Kirin, Kyorin Pharmaceutical, and GSK; Nagio Takigawa: personal fees as honoraria from Boehringer-Ingelheim Japan, Chugai Pharmaceutical, Eli Lilly Japan, Ono Pharmaceutical, AstraZeneca, Bristol-Myers Squibb Company Japan, Daiichi-Sankyo Pharmaceutical, Taiho Pharmaceutical, Pfizer Inc. Japan, Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., MSD, and Kyowa Hakko Kirin. Kazuma Kishi: research funding and personal fees as honoraria from Boehringer Ingelheim; Yusuke Okuma: research funding, advisory fee, and personal fees as honoraria from AstraZeneca; research funding from AbbVie and Merck Sharp & Dohme; and personal fees as honoraria from and Chugai Pharmaceutical, Eisai, Eli Lilly, MSD, Ono Pharmaceutical, Takeda Pharmaceutical, and Taiho Pharmaceutical; Akira Togashi: employee of Boehringer Ingelheim; Nobuhiko Seki: research funding and personal fees as honoraria from Eli Lilly, Ono Pharmaceutical, Boehringer Ingelheim, Taiho Pharmaceutical, Chugai Pharmaceutical, Takeda Pharmaceutical, Nippon Kayaku, Pfizer, and Daiichi Sankyo; research funding from Eisai and Shionogi; and personal fees as honoraria from AstraZeneca, MSD, Bristol Myers Squibb, Novartis, and Kyowa Kirin. No potential conflicts of interest were disclosed by the other authors.
